These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37057368)

  • 41. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study.
    Salerno-Uriarte JA; De Ferrari GM; Klersy C; Pedretti RF; Tritto M; Sallusti L; Libero L; Pettinati G; Molon G; Curnis A; Occhetta E; Morandi F; Ferrero P; Accardi F;
    J Am Coll Cardiol; 2007 Nov; 50(19):1896-904. PubMed ID: 17980258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beyond Ejection Fraction: Novel Clinical Approaches Towards Sudden Cardiac Death Risk Stratification in Patients with Dilated Cardiomyopathy.
    Pour-Ghaz I; Heckle M; Ifedili I; Kayali S; Nance C; Kabra R; Jha SK; Jefferies JL; Levine YC
    Curr Cardiol Rev; 2022; 18(2):e040821195265. PubMed ID: 34348632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT).
    Bänsch D; Antz M; Boczor S; Volkmer M; Tebbenjohanns J; Seidl K; Block M; Gietzen F; Berger J; Kuck KH
    Circulation; 2002 Mar; 105(12):1453-8. PubMed ID: 11914254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term follow-up of arrhythmogenic right ventricular cardiomyopathy patients with an implantable cardioverter-defibrillator for prevention of sudden cardiac death.
    Yin K; Ding L; Li Y; Hua W
    Clin Cardiol; 2017 Apr; 40(4):216-221. PubMed ID: 28139837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of signal-averaged electrocardiography findings on appropriate shocks in prophylactic implantable cardioverter defibrillator patients with nonischemic systolic heart failure.
    Nomoto M; Suzuki A; Shiga T; Shoda M; Hagiwara N
    BMC Cardiovasc Disord; 2022 Aug; 22(1):374. PubMed ID: 35974317
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study.
    Passman R; Subacius H; Ruo B; Schaechter A; Howard A; Sears SF; Kadish A
    Arch Intern Med; 2007 Nov; 167(20):2226-32. PubMed ID: 17998496
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
    Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
    Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
    Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C
    Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Left atrial booster pump function is an independent predictor of subsequent life-threatening ventricular arrhythmias in non-ischaemic cardiomyopathy.
    Negishi K; Negishi T; Zardkoohi O; Ching EA; Basu N; Wilkoff BL; Popović ZB; Marwick TH
    Eur Heart J Cardiovasc Imaging; 2016 Oct; 17(10):1153-60. PubMed ID: 26710819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
    BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death].
    Lelakowski J; Pudło J; Lelakowska-Pieła M; Rydlewska A; Piekarz J; Domaracki D
    Pol Merkur Lekarski; 2016 Apr; 40(238):216-22. PubMed ID: 27137820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonsustained ventricular tachycardia in dilated cardiomyopathy.
    Cuoco FA; Singh SN
    Curr Cardiol Rep; 2005 Sep; 7(5):368-75. PubMed ID: 16105493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Predictive parameters of occurrence of adequate interventions in patients with implanted cardioverter-defibrillators with or without resynchronisation therapy in primary prevention of sudden cardiac death in dilated cardiomyopathy].
    Lelakowski J; Rydlewska A; Lelakowska M; Pudło J; Piekarz J
    Pol Merkur Lekarski; 2017 Feb; 42(248):65-70. PubMed ID: 28258679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy.
    Zecchin M; Di Lenarda A; Proclemer A; Faganello G; Facchin D; Petz E; Sinagra G
    Europace; 2004 Sep; 6(5):400-6. PubMed ID: 15294264
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implantable cardioverter defibrillators in patients with valvular cardiomyopathy.
    Valles AG; Khawaja FJ; Gersh BJ; Enriquez-Sarano M; Friedman PA; Park SJ; Hodge DO; Cha YM
    J Cardiovasc Electrophysiol; 2012 Dec; 23(12):1326-32. PubMed ID: 23130974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum markers of collagen turnover predict future shocks in implantable cardioverter-defibrillator recipients with dilated cardiomyopathy on optimal treatment.
    Kanoupakis EM; Manios EG; Kallergis EM; Mavrakis HE; Goudis CA; Saloustros IG; Milathianaki ME; Chlouverakis GI; Vardas PE
    J Am Coll Cardiol; 2010 Jun; 55(24):2753-9. PubMed ID: 20538169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiac MRI to Predict Sudden Cardiac Death Risk in Dilated Cardiomyopathy.
    Li Y; Xu Y; Li W; Guo J; Wan K; Wang J; Xu Z; Han Y; Sun J; Chen Y
    Radiology; 2023 May; 307(3):e222552. PubMed ID: 36916890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators.
    Kadish A; Schaechter A; Subacius H; Thattassery E; Sanders W; Anderson KP; Dyer A; Goldberger J; Levine J
    J Am Coll Cardiol; 2006 Jun; 47(12):2477-82. PubMed ID: 16781376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096098
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term follow-up of prophylactic implantable cardioverter-defibrillator-only therapy: comparison of ischemic and nonischemic heart disease.
    Smith T; Theuns DA; Caliskan K; Jordaens L
    Clin Cardiol; 2011 Dec; 34(12):761-7. PubMed ID: 22038531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.